Hasik, Rheims & Partners
We are only able to display limited information for this firm. We display more complete information for all of the following firms:
Well-regarded for its ‘deep expertise, practical approach, and strong client focus’, Hasik, Rheims & Partners’ IP practice remains a trusted name for brand prosecution, management and enforcement across copyright, design and patent work. At the helm of the practice is a trio of experts: Daniel Hasik, advises across the full spectrum of trade marks, patents, designs and unfair competition; Eric Rheims, who offers sector-specific insight in the luxury and pharmaceutical spaces; and Anna Kruszewska, whose practice spans copyright, media matters and the protection of personal rights. Joanna Wozniak advises a broad client base, ranging from luxury goods and cosmetics brands to artists, film and theatre producers, software houses and patent owners.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- ‘Hasik, Rheims & Partners stands out for its deep expertise, practical approach, and strong client focus. The IP team is highly responsive, commercially minded, and adept at handling both contentious and non-contentious matters.'
- ‘Daniel Hasik and Joanna Wozniak, the individuals I have worked with at Hasik, Rheims & Partners, stand out for their combination of legal expertise, responsiveness, and genuine dedication to our client. What sets them apart from competitors is their ability to combine deep knowledge of Polish law with a practical, business-minded perspective, ensuring advice is not only accurate but also actionable.'
Key clients
- Wazdan Holding Limited UEFA Lacoste, Longchamp, Louis Vuitton, Moschino, Superdry, Givenchy, Kenzo, Celine, Marc Jacobs, Hugo Boss, Tommy Hilfiger, The Kooples, Ralph Lauren, Versace Merck Sharp & Dohme, Eli Lilly, Pfizer, Novartis, Sandoz, Sanofi, Organon Secto Design MOOOI Gedeon Richter CD Projekt
Work highlights
Representing Gedeon Richter in a patent dispute against Bayer AG concerning the drug Xarelto.